These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27817873)

  • 1. Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark.
    Hostenkamp G; Fischer KE; Borch-Johnsen K
    Health Policy; 2016 Dec; 120(12):1404-1411. PubMed ID: 27817873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.
    Niyomnaitham S; Page A; La Caze A; Whitfield K; Smith AJ
    BMC Health Serv Res; 2014 Apr; 14():151. PubMed ID: 24708579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan.
    Hsu JC; Cheng CL; Ross-Degnan D; Wagner AK; Zhang F; Kao Yang YH; Liu LL; Tai HY; Chen KH; Yang PW; Lu CY
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1026-35. PubMed ID: 26251229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone.
    Stewart KA; Natzke BM; Williams T; Granger E; Casscells SW; Croghan TW
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1048-52. PubMed ID: 19655338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.
    Ruiter R; Visser LE; van Herk-Sukel MP; Geelhoed-Duijvestijn PH; de Bie S; Straus SM; Mol PG; Romio SA; Herings RM; Stricker BH
    Drug Saf; 2012 Jun; 35(6):471-80. PubMed ID: 22540371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rise and fall of the thiazolidinediones: impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones.
    Hashim S; Gomes T; Juurlink D; Hellings C; Mamdani M
    J Popul Ther Clin Pharmacol; 2013; 20(3):e238-42. PubMed ID: 24141901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.
    Leal I; Romio SA; Schuemie M; Oteri A; Sturkenboom M; Trifirò G
    Br J Clin Pharmacol; 2013 Mar; 75(3):861-8. PubMed ID: 22845019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report.
    Pai SA; Kshirsagar NA
    Indian J Med Res; 2016 Nov; 144(5):672-681. PubMed ID: 28361819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responding to an FDA warning--geographic variation in the use of rosiglitazone.
    Shah ND; Montori VM; Krumholz HM; Tu K; Alexander GC; Jackevicius CA
    N Engl J Med; 2010 Nov; 363(22):2081-4. PubMed ID: 21083379
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.
    Jain R; Mullins CD; Lee H; Wong W
    Res Social Adm Pharm; 2012; 8(1):47-59. PubMed ID: 21733760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.
    Hesse U; Godman B; Petzold M; Martin A; Malmström RE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):677-85. PubMed ID: 24105097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of thiazolidinediones.
    Tolman KG
    Expert Opin Drug Saf; 2011 May; 10(3):419-28. PubMed ID: 21366501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008.
    Rohatgi A; McGuire DK
    Cardiovasc Drugs Ther; 2008 Jun; 22(3):233-40. PubMed ID: 18373186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.
    Hall GC; Smith HT; Curtis B; McMahon AD
    Int J Clin Pract; 2011 May; 65(5):586-91. PubMed ID: 21489082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reimbursement decision-making and prescription patterns of glitazones in treatment of type 2 diabetes mellitus patients in Denmark.
    Iversen PB; Vondeling H
    Health Care Anal; 2006 Jun; 14(2):79-89. PubMed ID: 17195576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies.
    Vondeling H; Iversen PB
    Eur J Health Econ; 2004 Oct; 5(3):263-9. PubMed ID: 15714347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.